Zeo ScientifiX's recent quarterly update underscores a 12.5% revenue increase driven chiefly by its PPX™ service platform, which now accounts for nearly 30% of total sales. This growth contrasts with declining revenues from its higher concentration allogenic biologics, attributed to intensifying market competition and pricing pressures. The company's business model combines sales of biologic products through medical groups and distributors alongside proprietary service offerings, but its competitive position remains constrained by limited scale and regulatory uncertainties. Liquidity remains a critical risk given ongoing losses and working capital deficits.